Pekin Singer Strauss Asset Management Position in Gilead Sciences (GILD) Upped by $981,600; Moors & Cabot Raised Position in Hanesbrands (HBI)

June 24, 2018 - By Kurt Siggers

Gilead Sciences, Inc. (NASDAQ:GILD) Logo

Pekin Singer Strauss Asset Management increased its stake in Gilead Sciences Inc (GILD) by 1308.8% based on its latest 2018Q1 regulatory filing with the SEC. Pekin Singer Strauss Asset Management bought 13,088 shares as the company’s stock declined 17.62% with the market. The institutional investor held 14,088 shares of the health care company at the end of 2018Q1, valued at $1.06M, up from 1,000 at the end of the previous reported quarter. Pekin Singer Strauss Asset Management who had been investing in Gilead Sciences Inc for a number of months, seems to be bullish on the $92.41 billion market cap company. The stock decreased 0.63% or $0.45 during the last trading session, reaching $71.07. About 4.11 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has risen 4.37% since June 24, 2017 and is uptrending. It has underperformed by 8.20% the S&P500. Some Historical GILD News: 09/04/2018 – POLL: Which of the recent large cell/gene therapy deals will work out best for the acquirer? $NVS $AVXS $CELG $GILD; 18/04/2018 – Astellas Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company; 30/05/2018 – GALAPAGOS – CO TO GET $15 MLN PAYMENT FROM GILEAD FOR PROGRESSION INTO PHASE 3 OF PHASE 2B/3 SELECTION STUDY OF FILGOTINIB IN ULCERATIVE COLITIS; 10/03/2018 – #2 Searching for HIV cure, Gilead’s new ‘shock and kill’ combo swats back lethal virus in monkeys $GILD; 21/03/2018 – STAT Plus: Gilead patent for its Sovaldi hepatitis C drug is rejected in Ukraine; 14/05/2018 – Gilead’s Epclusa Falls After 3-Wk Rise, Mavyret Advances: Hep-C; 16/04/2018 – Gilead’s Harvoni Falls For 2nd Wk, Epclusa Declines: Hep-C; 05/03/2018 – GLAXOSMITHKLINE STUDIED DOLUTEGRAVIR IN HIV, TUBERCULOSIS; 15/05/2018 – Gilead’s Kite Announces New Worldwide Facilities and Expanded Collaboration With National Cancer Institute to Support Cell Therapy Pipeline; 05/03/2018 – GILEAD SCIENCES – THROUGH 48 WEEKS, BIKTARVY FOUND NON-INFERIOR TO ABACAVIR-CONTAINING REGIMEN IN VIROLOGICALLY SUPPRESSED ADULTS LIVING WITH HIV

Moors & Cabot Inc increased its stake in Hanesbrands Inc (HBI) by 170.58% based on its latest 2018Q1 regulatory filing with the SEC. Moors & Cabot Inc bought 17,208 shares as the company’s stock declined 10.22% with the market. The institutional investor held 27,296 shares of the clothing and shoe and accessory stores company at the end of 2018Q1, valued at $503,000, up from 10,088 at the end of the previous reported quarter. Moors & Cabot Inc who had been investing in Hanesbrands Inc for a number of months, seems to be bullish on the $7.91 billion market cap company. The stock decreased 0.36% or $0.08 during the last trading session, reaching $21.96. About 11.08 million shares traded or 57.58% up from the average. Hanesbrands Inc. (NYSE:HBI) has declined 10.39% since June 24, 2017 and is downtrending. It has underperformed by 22.96% the S&P500. Some Historical HBI News: 22/04/2018 – DJ Hanesbrands Inc, Inst Holders, 1Q 2018 (HBI); 15/05/2018 – HANESBRANDS INC HBI.N SEES FY 2018 SALES $6.72 BLN TO $6.82 BLN; 24/04/2018 – IFABRIC – RENEWAL OF ITS KEY MAIDENFORM LICENSE AND DISTRIBUTION AGREEMENT WITH MFB INTERNATIONAL HOLDINGS S.A.R.L., A UNIT OF HANESBRANDS INC; 15/05/2018 – HANESBRANDS INC HBI.N FY2018 SHR VIEW $1.76, REV VIEW $6.77 BLN — THOMSON REUTERS l/B/E/S

Pekin Singer Strauss Asset Management, which manages about $1.07 billion and $543.35M US Long portfolio, decreased its stake in Abbvie Inc (NYSE:ABBV) by 11,939 shares to 38,584 shares, valued at $3.65M in 2018Q1, according to the filing. It also reduced its holding in Jones Lang Lasalle Inc (NYSE:JLL) by 13,885 shares in the quarter, leaving it with 101,819 shares, and cut its stake in Boeing Co (NYSE:BA).

More notable recent Gilead Sciences, Inc. (NASDAQ:GILD) news were published by: Seekingalpha.com which released: “Gilead: Growth Pick For Your Portfolio” on June 15, 2018, also Seekingalpha.com with their article: “The Kite Killer – TapImmune And Marker Merger Challenges Gilead” published on May 30, 2018, Benzinga.com published: “Cramer: Gilead Is Dead Money” on June 01, 2018. More interesting news about Gilead Sciences, Inc. (NASDAQ:GILD) were released by: Seekingalpha.com and their article: “Gilead’s Evolution In Oncology, With Comments On Valuation” published on June 07, 2018 as well as Seekingalpha.com‘s news article titled: “Does Gilead Have An HBV Blockbuster Drug In The Works?” with publication date: June 19, 2018.

Investors sentiment increased to 0.88 in Q1 2018. Its up 0.08, from 0.8 in 2017Q4. It improved, as 71 investors sold GILD shares while 519 reduced holdings. 114 funds opened positions while 404 raised stakes. 976.44 million shares or 0.39% more from 972.68 million shares in 2017Q4 were reported. Edgemoor Invest Incorporated owns 130,327 shares or 1.31% of their US portfolio. Atria Invs Ltd Limited Liability Company stated it has 66,531 shares or 0.24% of all its holdings. Bnp Paribas Asset Management holds 0.55% or 861,651 shares. Mark Sheptoff Financial Planning Limited invested in 8,887 shares or 0.46% of the stock. Linscomb Williams has invested 0.04% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Balasa Dinverno Foltz Lc accumulated 20,841 shares. Rockland Trust Communication invested 0.03% in Gilead Sciences, Inc. (NASDAQ:GILD). Dorsey & Whitney Trust Limited Liability Com reported 7,969 shares. Griffin Asset Management Incorporated, a New York-based fund reported 30,087 shares. Mariner holds 0.21% or 76,573 shares in its portfolio. Mariner Wealth Advisors holds 0.09% or 20,171 shares in its portfolio. Kingfisher Capital Limited Com holds 0.15% or 3,041 shares. Rfg Advisory owns 5,727 shares. Dreman Value Management L L C stated it has 13,871 shares or 0.47% of all its holdings. Bedell Frazier Inv Counseling Ltd Com, California-based fund reported 109,504 shares.

Since January 2, 2018, it had 0 insider purchases, and 23 insider sales for $48.21 million activity. $472,065 worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares were sold by Cogan John Francis. Another trade for 30,000 shares valued at $2.37M was made by Alton Gregg H on Thursday, January 11. MARTIN JOHN C also sold $3.41 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Friday, June 1. The insider Meyers James R sold 100,000 shares worth $8.02M. Washington Robin L also sold $401,566 worth of Gilead Sciences, Inc. (NASDAQ:GILD) shares.

Among 31 analysts covering Gilead Sciences (NASDAQ:GILD), 22 have Buy rating, 0 Sell and 9 Hold. Therefore 71% are positive. Gilead Sciences had 132 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Outperform” rating by Oppenheimer on Tuesday, October 20. Credit Suisse maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, September 14 with “Outperform” rating. Morgan Stanley maintained the shares of GILD in report on Friday, October 6 with “Equal-Weight” rating. The rating was maintained by BMO Capital Markets with “Hold” on Tuesday, January 2. As per Friday, February 5, the company rating was initiated by Leerink Swann. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by Maxim Group on Friday, February 12. The stock has “Buy” rating by Robert W. Baird on Friday, September 15. Jefferies upgraded the shares of GILD in report on Tuesday, September 6 to “Buy” rating. As per Monday, August 28, the company rating was maintained by Maxim Group. The firm earned “Overweight” rating on Thursday, November 5 by Piper Jaffray.

Since February 15, 2018, it had 4 insider purchases, and 2 selling transactions for $315,171 activity. Another trade for 21,890 shares valued at $382,418 was made by Hytinen Barry on Thursday, May 17. SINGER DAVID V bought $553,456 worth of stock. The insider Evans Gerald bought 17,500 shares worth $309,050. Faircloth Michael E. had sold 26,922 shares worth $538,978. Upchurch W Howard Jr had sold 51,743 shares worth $1.07M.

Among 21 analysts covering Hanesbrands (NYSE:HBI), 10 have Buy rating, 0 Sell and 11 Hold. Therefore 48% are positive. Hanesbrands had 65 analyst reports since September 17, 2015 according to SRatingsIntel. The rating was maintained by Buckingham Research with “Buy” on Thursday, November 2. Buckingham Research reinitiated Hanesbrands Inc. (NYSE:HBI) on Monday, July 17 with “Buy” rating. Stifel Nicolaus maintained Hanesbrands Inc. (NYSE:HBI) on Friday, February 3 with “Hold” rating. The stock of Hanesbrands Inc. (NYSE:HBI) earned “Outperform” rating by Wells Fargo on Thursday, October 22. The stock has “Equal-Weight” rating by Morgan Stanley on Monday, February 27. The firm earned “Hold” rating on Wednesday, September 27 by Cowen & Co. Morgan Stanley maintained Hanesbrands Inc. (NYSE:HBI) on Monday, August 7 with “Equal-Weight” rating. The firm has “Neutral” rating by Nomura given on Thursday, November 2. The company was initiated on Monday, October 23 by Deutsche Bank. The stock of Hanesbrands Inc. (NYSE:HBI) earned “Market Perform” rating by Wells Fargo on Friday, February 9.

Moors & Cabot Inc, which manages about $756.58M US Long portfolio, decreased its stake in Eastman Chem Co (NYSE:EMN) by 3,774 shares to 6,727 shares, valued at $710,000 in 2018Q1, according to the filing. It also reduced its holding in Royal Bk Cda Montreal Que (NYSE:RY) by 4,557 shares in the quarter, leaving it with 7,315 shares, and cut its stake in At&T Inc (NYSE:T).

Investors sentiment decreased to 0.87 in 2018 Q1. Its down 0.24, from 1.11 in 2017Q4. It fall, as 74 investors sold HBI shares while 192 reduced holdings. 60 funds opened positions while 171 raised stakes. 338.62 million shares or 0.25% more from 337.77 million shares in 2017Q4 were reported. Kings Point Capital holds 0.28% in Hanesbrands Inc. (NYSE:HBI) or 75,984 shares. 104,544 were reported by Rothschild Inv Il. 161,130 were accumulated by Advantage. Old Mutual Customised Solutions (Proprietary) Limited invested in 0.04% or 22,600 shares. Next Grp Inc reported 22,700 shares. Epoch Inv Inc owns 0.04% invested in Hanesbrands Inc. (NYSE:HBI) for 555,939 shares. Geode Capital Mgmt Limited Liability holds 0.02% or 4.01 million shares in its portfolio. Chieftain Mgmt invested 17.14% in Hanesbrands Inc. (NYSE:HBI). Moreover, First Manhattan Company has 0% invested in Hanesbrands Inc. (NYSE:HBI). San Francisco Sentry Invest Group (Ca) owns 80 shares for 0% of their portfolio. Vnbtrust National Association has invested 0.11% in Hanesbrands Inc. (NYSE:HBI). Citigroup has invested 0% in Hanesbrands Inc. (NYSE:HBI). The Montana-based Da Davidson has invested 0.23% in Hanesbrands Inc. (NYSE:HBI). 38,552 are owned by Dnb Asset Mgmt As. Commerzbank Aktiengesellschaft Fi holds 0.01% or 36,034 shares in its portfolio.

Gilead Sciences, Inc. (NASDAQ:GILD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: